UNLABELLED: Although it is known that neurofibromatosis 1 (NF1) patients suffer from vitamin D deficiency and display decreased bone mineral density (BMD), a systematic clinical and histomorphometrical analysis is absent. Our data demonstrate that NF1 patients display high bone turnover and accumulation of osteoid and that supplementation of vitamin D has a beneficial effect on their BMD. INTRODUCTION: Neurofibromatosis 1 results in a wide range of clinical manifestations, including decreased BMD. Although it has been reported that NF1 patients have decreased vitamin D serum levels, the manifestation of the disease at the bone tissue level has rarely been analyzed. METHODS: Thus, we performed a clinical evaluation of 14 NF1 patients in comparison to age- and sex-matched control individuals. The analysis included dual X-ray absorptiometry osteodensitometry, laboratory parameters, histomorphometric and quantitative backscattered electron imaging (qBEI) analyses of undecalcified bone biopsies. RESULTS: NF1 patients display significantly lower 25-(OH)-cholecalciferol serum levels and decreased BMD compared to control individuals. Histomorphometric analysis did not only reveal a reduced trabecular bone volume in biopsies from NF1 patients, but also a significantly increased osteoid volume and increased numbers of osteoblasts and osteoclasts. Moreover, qBEI analysis revealed a significant decrease of the calcium content in biopsies from NF1 patients. To address the question whether a normalization of calcium homeostasis improves BMD in NF1 patients, we treated four patients with cholecalciferol for 1 year, which resulted in a significant increase of BMD. CONCLUSION: Taken together, our data provide the first complete histomorphometric analysis from NF1 patients. Moreover, they suggest that low vitamin D levels significantly contribute to the skeletal defects associated with the disease.
UNLABELLED: Although it is known that neurofibromatosis 1 (NF1) patients suffer from vitamin D deficiency and display decreased bone mineral density (BMD), a systematic clinical and histomorphometrical analysis is absent. Our data demonstrate that NF1patients display high bone turnover and accumulation of osteoid and that supplementation of vitamin D has a beneficial effect on their BMD. INTRODUCTION:Neurofibromatosis 1 results in a wide range of clinical manifestations, including decreased BMD. Although it has been reported that NF1patients have decreased vitamin D serum levels, the manifestation of the disease at the bone tissue level has rarely been analyzed. METHODS: Thus, we performed a clinical evaluation of 14 NF1patients in comparison to age- and sex-matched control individuals. The analysis included dual X-ray absorptiometry osteodensitometry, laboratory parameters, histomorphometric and quantitative backscattered electron imaging (qBEI) analyses of undecalcified bone biopsies. RESULTS:NF1patients display significantly lower 25-(OH)-cholecalciferol serum levels and decreased BMD compared to control individuals. Histomorphometric analysis did not only reveal a reduced trabecular bone volume in biopsies from NF1patients, but also a significantly increased osteoid volume and increased numbers of osteoblasts and osteoclasts. Moreover, qBEI analysis revealed a significant decrease of the calcium content in biopsies from NF1patients. To address the question whether a normalization of calcium homeostasis improves BMD in NF1patients, we treated four patients with cholecalciferol for 1 year, which resulted in a significant increase of BMD. CONCLUSION: Taken together, our data provide the first complete histomorphometric analysis from NF1patients. Moreover, they suggest that low vitamin D levels significantly contribute to the skeletal defects associated with the disease.
Authors: Heike A Bischoff-Ferrari; Thomas Dietrich; E John Orav; Frank B Hu; Yuqing Zhang; Elisabeth W Karlson; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2004-09 Impact factor: 7.045
Authors: David A Stevenson; Laurie J Moyer-Mileur; Mary Murray; Hillarie Slater; Xiaoming Sheng; John C Carey; Bukhosi Dube; David H Viskochil Journal: J Pediatr Date: 2007-01 Impact factor: 4.406
Authors: Tommi Kuorilehto; Erika Ekholm; Marja Nissinen; Kalevi Hietaniemi; Ari Hiltunen; Pekka Paavolainen; Risto Penttinen; Juha Peltonen Journal: J Histochem Cytochem Date: 2005-11-28 Impact factor: 2.479
Authors: D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali Journal: Clin Genet Date: 2011-01-19 Impact factor: 4.438
Authors: David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous Journal: J Pediatr Endocrinol Metab Date: 2011 Impact factor: 1.634
Authors: Maya B Lodish; Urania Dagalakis; Ninet Sinaii; Ethan Bornstein; Aerang Kim; Kelsey B Lokie; Andrea M Baldwin; James C Reynolds; Eva Dombi; Constantine A Stratakis; Brigitte C Widemann Journal: Endocr Relat Cancer Date: 2012-11-19 Impact factor: 5.678
Authors: Yongzheng He; Steven D Rhodes; Shi Chen; Xiaohua Wu; Jin Yuan; Xianlin Yang; Li Jiang; Xianqi Li; Naoyuki Takahashi; Mingjiang Xu; Khalid S Mohammad; Theresa A Guise; Feng-Chun Yang Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240
Authors: Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay Journal: Genet Med Date: 2018-04-26 Impact factor: 8.822